Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest announces nebivolol study results

Forest announces nebivolol study results

5th November 2007

Forest Laboratories has announced the results of a study of nebivolol, with a significant reduction in sitting diastolic and systolic blood pressure when the compound is used as a monotherapy in African-American patients with stage I-II hypertension.

Furthermore, the results – published in the November issue of the Journal of Clinical Hypertension – showed that the compound was well tolerated when compared to placebo, with a low incidence of fatigue, depression, sexual dysfunction and other typical beta blocker side effects.

The trial also showed that the compound was not associated with adverse changes in the levels of glucose and lipids in the blood.

Nebivolol is a selective beta 1-blocker approved in over 50 countries worldwide as a treatment for hypertension as a result of its vasodilating properties.

Elijah Saunders, professor of medicine and head of the hypertension section at the University of Maryland School of Medicine, said: “The findings of this study are important considering the excessive burden of high blood pressure in African Americans and the need for new treatment options.”

He added that this type of progress is especially important as African Americans have traditionally responded poorly to beta blockers as a treatment for hypertension.

In May 2007, Forest reported that clinical trial results had shown Nebivolol to be a useful treatment for hypertension for a wide range of patient populations.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.